Oral peptides and the gut barrier: what gets through

Key takeaways

• Most peptides make poor pills. In gastric and intestinal fluids, larger peptides (roughly 12 or more residues) degrade fast while small peptides resist it, so getting a peptide past the gut is a formulation problem .
• Tight junctions (claudins, occludins, ZO proteins) between gut cells control what passes between them. Larazotide, an eight-residue tight-junction modulator, was studied in celiac disease, but its phase 3 trial was terminated in 2022 .
• KPV, a tripeptide fragment of alpha-MSH, reduces inflammation in mouse colitis models through the PepT1 transporter and independent of melanocortin receptors; there is no completed human trial and no FDA-approved KPV product .
• Oral semaglutide (Rybelsus) reaches only about 1 percent absolute bioavailability, and only with the SNAC absorption enhancer plus an empty-stomach dose taken at least 30 minutes before food .
• Only a few oral peptide drugs are FDA-approved. Injection is still the dominant route because the gut barrier keeps oral absorption low even when the molecule survives digestion.

The stomach is a protease bath most peptides do not survive

The fasted human stomach sits at a pH of about 1.5 to 3.5 and is full of pepsin, the main gastric protease. Most therapeutic peptides do not pass through it intact. Pepsin cuts at hydrophobic and aromatic residues, and the acid alone unfolds structure that depends on disulfide bonds or salt bridges. When one group measured 17 peptide drugs in gastric and intestinal fluids, the larger peptides (insulin, calcitonin, glucagon, secretin, somatostatin) degraded quickly, while peptides under roughly 12 residues held up much better .

GLP-1 shows the problem in miniature. Native GLP-1 has a circulating half-life of only 1 to 2 minutes because dipeptidyl peptidase 4 cleaves it at the N-terminus. Oral semaglutide (Rybelsus) is the only oral GLP-1 receptor agonist on the market, and it works only because it is co-formulated with the absorption enhancer SNAC (salcaprozate sodium), which raises the local pH around the tablet and helps a little semaglutide cross the stomach lining intact . Absolute bioavailability is still only about 1 percent, usable only because semaglutide is potent enough that a sliver of the dose does the job.

What enteric coatings actually do, and why they help only some peptides

An enteric coating is a polymer shell (methacrylic acid copolymers like Eudragit, or hydroxypropyl methylcellulose phthalate) that stays intact in stomach acid and dissolves at the higher pH of the upper small intestine, around pH 5.5 to 6.5. It carries the payload through the stomach and releases it in the duodenum or jejunum.

The problem is what waits in the small intestine: pancreatic proteases (trypsin, chymotrypsin, elastase, carboxypeptidases) released with a meal. They work at neutral to slightly alkaline pH and cut at different bonds than pepsin. A peptide that survived the stomach because of an enteric coating can still be shredded in the small intestine if it carries trypsin or chymotrypsin cleavage sites.

• Enteric coating is necessary but not sufficient for oral bioavailability of most peptides.
• Peptides cyclized through head-to-tail amide or disulfide bonds resist small-intestinal proteases better than linear sequences.
• Backbone changes (N-methylation, D-amino acid substitution, PEGylation) extend gut residence time but can lower receptor affinity.
• Permeation enhancers (SNAC, sodium caprate, cell-penetrating peptide tags) are the second tool, each with its own pharmacokinetics and tolerability.

Tight junctions, zonulin, and the larazotide story

The intestinal epithelium is one cell thick, sealed at the top by tight junctions: complexes of claudins, occludins, and zonula occludens proteins that set how much can pass between cells. Most peptides cross the barrier between cells only when those junctions transiently open, so the biology that controls the tight junction matters for oral delivery.

Zonulin is a protein described as loosening tight junctions through an EGF-receptor pathway, and it became popular as a blood marker of a leaky gut. That marker is now disputed: the commercial ELISA kits used to measure zonulin were later shown to detect unrelated proteins rather than zonulin itself, so many zonulin readings do not reflect actual zonulin levels . The tight-junction biology is real; the popular serum test for it is on shakier ground.

Larazotide acetate (AT-1001) is a synthetic eight-residue peptide that blocks zonulin signaling and reduces tight-junction opening. A phase 2 trial in celiac patients who still had symptoms on a gluten-free diet found the 0.5 mg dose beat placebo , but the phase 3 program (NCT03569007) was terminated by the sponsor in 2022 . Larazotide is the mirror image of the oral-delivery problem: it works on the barrier itself instead of trying to cross it, so its trials measured intestinal permeability and symptom burden rather than blood drug levels.

KPV and the localized anti-inflammatory pattern

KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (lysine-proline-valine). In mouse colitis models, oral or intracolonic KPV reduced inflammation. It was taken up through the PepT1 di/tripeptide transporter into intestinal epithelial cells and leukocytes, where it acts inside the cell to damp NF-kB and MAP-kinase signaling, and the effect did not depend on melanocortin receptors .

KPV has not completed a phase 3 human trial in inflammatory bowel disease, and there is no FDA-approved KPV product. Its small size (three residues), lack of obvious protease cleavage sites, and apparent action right at the gut wall keep it in circulation as a research peptide, but the missing piece is late-stage human evidence. The mouse and cell data are not a human efficacy claim.

BPC-157 and the systemic question for oral peptides

BPC-157 is a synthetic 15-residue peptide (a pentadecapeptide). It is often described as orally bioavailable in humans on the strength of rodent studies that dosed it by mouth. The published data do not support that leap. Rodent gut physiology differs from human physiology in pH, transit time, microbial makeup, and protease activity, so a peptide that survives a rat's small intestine may not survive a human's, and the reverse can be true too.

There is no published human pharmacokinetic study of oral BPC-157. Claims of systemic activity after oral dosing rest on rodent data plus user reports . As of 2026, BPC-157 still has no completed, peer-reviewed human efficacy trial and is not FDA-approved for any indication. It may act locally in the gut wall through a route similar to KPV, but any systemic effect after swallowing it is unverified in humans.

What this means for readers and prescribers

• Judge any oral peptide claim against three barriers: surviving gastric acid and pepsin, surviving pancreatic proteases in the small intestine, and actually crossing the epithelium. Each one needs a credible answer.
• Enteric coating solves the first barrier only. It does nothing about pancreatic proteases or crossing the epithelium.
• Permeation enhancers like SNAC are the only validated way to reach the bloodstream in an approved oral peptide product, and even then bioavailability is low (about 1 percent for oral semaglutide) .
• Locally acting peptides (KPV, larazotide) do not need to reach the bloodstream to work, so their trials reasonably measure local effects and permeability rather than plasma drug levels.
• Animal data, rodent studies especially, predict human oral bioavailability poorly for peptides. Human PK is the only reliable basis for an oral dosing claim.

For research and educational purposes only. Not medical advice.

pepSmart has not commissioned independent clinical review of this article.

More on how we write and source these pieces: Editorial process and contributor disclosure and Sourcing posture.

Spot an error? Email corrections via /about.

Sources: 7 entries, all primary canon (PubMed, ClinicalTrials.gov, and the FDA drug label), last reviewed 2026-07-08.

Related tools

• GLP-1 conversion calculator - Convert a GLP-1 mg dose to U-100 units and ml.
• GLP-1 ramp planner - Preview a linear educational dose-step table.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.
• PK simulator overview - Public overview of the Pro pharmacokinetic simulator.
• Semaglutide dose calculator - Run semaglutide-focused vial draw math.
• Peptide reconstitution calculator - Convert vial mass and BAC water volume into mcg/ml.